keyword
MENU ▼
Read by QxMD icon Read
search

Nhl

keyword
https://www.readbyqxmd.com/read/28822981/spectrum-of-lymphomas-across-different-drug-treatment-groups-in-rheumatoid-arthritis-a-european-registries-collaborative-project
#1
Louise K Mercer, Anne C Regierer, Xavier Mariette, William G Dixon, Eva Baecklund, Karin Hellgren, Lene Dreyer, Merete Lund Hetland, René Cordtz, Kimme Hyrich, Anja Strangfeld, Angela Zink, Helena Canhao, M Victoria Hernandez, Florence Tubach, Jacques-Eric Gottenberg, Jacques Morel, Jakub Zavada, Florenzo Iannone, Johan Askling, Joachim Listing
BACKGROUND: Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes. METHODS: Patients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma...
August 19, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28822058/immune-dysfunction-in-non-hodgkin-lymphoma-avenues-for-new-immunotherapy-based-strategies
#2
REVIEW
Lorenzo Falchi
PURPOSE OF THIS REVIEW: The present review focuses on key aspects of non-Hodgkin lymphoma (NHL) evasion of immune surveillance and how these can be leveraged to devise effective immunotherapy strategies. RECENT FINDINGS: In recent years, significant progress has been made in the field of cancer immunotherapy. In particular, the remarkable clinical results of anti-programmed death (PD)-1/PD-ligand (L)1 antibodies are revolutionizing the treatment approach to multiple solid and hematologic tumors...
August 18, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28818867/exploring-potential-germline-associated-roles-of-the-trim-nhl-protein-nhl-2%C3%A2-through-rnai-screening
#3
Gregory M Davis, Wai Y Low, Joshua W T Anderson, Peter R Boag
TRIM-NHL proteins are highly conserved regulators of developmental pathways in vertebrates and invertebrates. The TRIM-NHL family member, NHL-2 in Caenorhabditis elegans functions as a miRNA cofactor to regulate developmental timing. Similar regulatory roles have been reported in other model systems, with the mammalian orthologue in mice, TRIM32, contributing to muscle and neuronal cell proliferation via miRNA activity. Given the interest associated with TRIM-NHL family proteins, we aimed to further investigate the role of NHL-2 in C...
August 17, 2017: G3: Genes—Genomes—Genetics
https://www.readbyqxmd.com/read/28816963/efficacy-and-safety-evaluation-of-fludarabine-based-chemotherapy-regimen-for-patients-with-non-hodgkin-lymphoma-a-meta-analysis
#4
Xiaoping Zhang, Zheng Ge, Baoan Chen, Ran Liu, Chong Gao
This meta-analysis was performed to evaluate the efficacy and safety of fludarabine (F)-based regimen for the treatment of non-Hodgkin lymphoma (NHL) compared with other regimens with no F contained.PubMed, Embase, Cochrane Library, Wanfang, VIP, and CNKI databases were searched to identify eligible literatures. R software version 3.12 was used for statistical analysis. Odds ratio (OR) with 95% confidence interval (CI) were utilized to express the complete response, overall response and adverse events outcomes...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28810201/the-association-between-non-hodgkin-lymphoma-and-organophosphate-pesticides-exposure-a-meta-analysis
#5
REVIEW
Liqin Hu, Dan Luo, Tingting Zhou, Yun Tao, Jingwen Feng, Surong Mei
Several epidemiological studies show the association between organophosphate pesticides (OPs) and the risk of non-Hodgkin lymphoma (NHL), yet various research results remain controversial. To explore the hazard of OPs exposure to human health, three kinds of OPs (Terbufos, Malathion, and Diazinon) that are non-halogenated aliphatic compounds were included in the meta-analysis. We searched PubMed and Web of Science Databases for articles published from 1985 to February 2017. The databases were also searched for eligible studies through a manual references search...
August 12, 2017: Environmental Pollution
https://www.readbyqxmd.com/read/28809998/temporal-association-of-herpes-zoster-eruption-post-aminolevulinic-acid-hydrochloride-photodynamic-therapy-for-actinic-keratoses
#6
Katie Manno, Joel L Cohen
<p>Herpes zoster is a common and painful disease caused by the reactivation of the varicella-zoster virus with a higher incidence and severity associated with increasing age as well as compromised immune status. Acute inciting events for this eruption are not always known, but can include illness, stress, and mechanical injury. Photodynamic therapy (PDT) is a widely used treatment modality for precancerous skin lesions that has not been previously associated with provoking a herpes zoster outbreak. We present a case of herpes zoster eruption occurring after PDT for actinic keratoses in a patient with Non-Hodgkin Lymphoma (NHL)...
August 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28806751/the-relative-age-effect-reversal-among-the-national-hockey-league-elite
#7
Luca Fumarco, Benjamin G Gibbs, Jonathan A Jarvis, Giambattista Rossi
Like many sports in adolescence, junior hockey is organized by age groups. Typically, players born after December 31st are placed in the subsequent age cohort and as a result, will have an age advantage over those players born closer to the end of the year. While this relative age effect (RAE) has been well-established in junior hockey and other professional sports, the long-term impact of this phenomenon is not well understood. Using roster data on North American National Hockey League (NHL) players from the 2008-2009 season to the 2015-2016 season, we document a RAE reversal-players born in the last quarter of the year (October-December) score more and command higher salaries than those born in the first quarter of the year...
2017: PloS One
https://www.readbyqxmd.com/read/28805292/incidence-and-outcomes-of-primary-central-nervous-system-lymphoma-in-solid-organ-transplant-recipients
#8
Parag Mahale, Meredith S Shiels, Charles F Lynch, Eric A Engels
Primary central nervous system lymphoma (PCNSL) risk is greatly increased in immunosuppressed HIV-infected people. Using data from the United States transplant registry linked with 17 cancer registries (1987-2014), we studied PCNSL and systemic non-Hodgkin lymphoma (NHL) in 288,029 solid organ transplant recipients. Transplant recipients had elevated incidence for PCNSL compared with the general population (standardized incidence ratio=65.1; N=168), and this elevation was stronger than for systemic NHL (standardized incidence ratio=11...
August 14, 2017: American Journal of Transplantation
https://www.readbyqxmd.com/read/28804691/combination-of-celecoxib-celebrex-%C3%A2-and-cd19-car-redirected-ctl-immunotherapy-for-the-treatment-of-b-cell-non-hodgkin-s-lymphomas
#9
REVIEW
Tam Nm Dinh, Alexandra S Onea, Ali R Jazirehi
The nonsteroidal anti-inflammatory drug (NSAID) Celecoxib (Celebrex(®)) received Food and Drug Administration (FDA) approval in 1998 for treatment of osteoarthritis and rheumatoid arthritis, and in recent years, its use has been extended to various types of malignancies, such as breast, colon, and urinary cancers. To maintain the survival of malignant B cells, non-Hodgkin's Lymphoma (NHL) is highly dependent on inflammatory microenvironment, and is inhibited by celecoxib. Celecoxib hinders tumor growth interacting with various apoptotic genes, such as cyclooxygenase-2 (Cox-2), B-cell lymphoma 2 (Bcl-2) family, phosphor-inositide-3 kinase/serine-threonine-specific protein kinase (PI3K/Akt), and inhibitors of apoptosis proteins (IAP) family...
2017: American Journal of Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28798034/fdg-pet-ct-in-lymphoma-has-imaging-directed-personalized-medicine-become-a-reality
#10
Sally F Barrington, Peter Wm Johnson
Positron emission tomography with computed tomography (PET-CT) using (18)F- fluorodeoxyglucose (FDG) is an essential part of the management of patients with lymphoma. Efforts to standardize PET acquisition and reporting, including the five-point 'Deauville scale', have enabled PET to become a surrogate for treatment success/failure in common lymphoma subtypes. This review summarizes the key evidence from clinical trials that supports PET-directed personalized approaches in lymphoma. PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selective radiotherapy...
August 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28797783/results-of-prospective-randomized-open-label-non-inferiority-study-of-tbo-filgrastim-granix-%C3%A2-versus-filgrastim-neupogen-%C3%A2-in-combination-with-plerixafor-for-autologous-stem-cell-mobilization-in-patients-with-multiple-myeloma-or-non-hodgkin-lymphoma
#11
Pavan Kumar Bhamidipati, Mark A Fiala, Brenda J Grossman, John F DiPersio, Keith Stokerl-Goldstein, Feng Gao, Geoffrey L Uy, Peter Westervelt, Mark A Schroeder, Amanda F Cashen, Camille N Abboud, Ravi Vij
Autologous hematopoietic stem cell transplantation (Auto- HSCT) improves survival in multiple myeloma (MM) and Non-Hodgkin lymphoma (NHL). Traditionally, filgrastim (Neupogen® - recombinant G-CSF) has been used in as a single agent or in combination with plerixafor for stem cell mobilization for auto-HSCT. In Europe, recombinant G-CSF biosimilar (Tevagrastim®) is approved for various indications similar to reference filgrastim, including stem cell mobilization for auto-HSCT; However, tbo- Filgrastim (Granix®) is registered under original biologic application and is not approved for stem cell mobilization in the USA...
August 7, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28797193/exposure-response-evaluations-of-venetoclax-efficacy-and-safety-in-patients-with-non-hodgkin-lymphoma
#12
Apurvasena Parikh, Sathej Gopalakrishnan, Kevin J Freise, Maria E Verdugo, Rajeev M Menon, Sven Mensing, Ahmed Hamed Salem
Exposure-response analyses were performed for a venetoclax monotherapy study in 106 patients with varying subtypes of non-Hodgkin lymphoma (NHL) (NCT01328626). Logistic regression, time-to-event, and progression-free survival (PFS) analyses were used to evaluate the relationship between venetoclax exposure, NHL subtype and response, PFS, or occurrence of serious adverse events. Trends for small increases in the probability of response with increasing venetoclax exposures were identified, and became more evident when assessed by NHL subtype...
August 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28794600/systemic-non-hodgkin-s-lymphoma-initially-presenting-as-a-bladder-mass
#13
Naveen Kumar Gupta, Dilip Kumar Pal
Urinary bladder lymphomas are rare lesions which may be primary bladder lymphomas or part of systemic lymphoma with bladder involvement. We report a case of non-Hodgkin's lymphoma (NHL) in a 73-year-old female who presented with bladder tumor which on evaluation revealed NHL with extensive systemic involvement. The management of such an advanced case is discussed here with literature review.
July 2017: Urology Annals
https://www.readbyqxmd.com/read/28781919/b-cell-lymphoma-presenting-as-multiple-nerve-sheath-tumors
#14
Jason Milton, Julie Renner, Victor Awuor
BACKGROUND: Diffuse Large B-cell Lymphoma (DLBCL) is the most common form of Non-Hodgkin lymphoma (NHL), accounting for 25-30 percent of cases in the United States.1 Extranodal sites are involved in approximately 40% of cases of DLBCL. CASE DESCRIPTION: In this report, we discuss the case of a patient with extranodal DLBCL within the cervical nerve roots that underwent surgical intervention due to the presence of cervical radiculopathy. CONCLUSION: The diagnosis of DLBCL was surprising given the appearance of the masses on MRI being similar to that of a neurofibroma or schwannoma...
2017: Surgical Neurology International
https://www.readbyqxmd.com/read/28774833/foxo-in-b-cell-lymphopoiesis-and-b-cell-neoplasia
#15
REVIEW
Alexey Ushmorov, Thomas Wirth
FOX O family transcription factors are important for differentiation and function of multiple cell types. In B lymphocytes they play a critical role. The activity of FOXOs is directly regulated both by signaling from B cell receptor (BCR) and cytokine receptors. FOXO1 action controls the transition between differentiation stages of B cell development. In comparison to other FOXO family members, FOXO1 plays a superior role in the regulation of early stages of B-cell differentiation. Although being known as a negative regulator of cell proliferation and therefore potential tumor suppressor, FOXO1 is downregulated only in Hodgkin lymphoma (HL) subtypes...
July 31, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/28766389/pharmacokinetics-efficacy-and-safety-of-the-rituximab-biosimilar-ct-p10
#16
Bertrand Coiffier
Rituximab, an anti-CD20 monoclonal antibody, is a key therapeutic in the treatment of B cell lymphomas and rheumatoid arthritis (RA). Global rates of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and RA are increasing, with a concomitant rise in individual and overall treatment costs. As such, biosimilar development may help facilitate greater access to treatment. The rituximab biosimilar CT-P10 (Truxima®) has recently received approval in Europe and South Korea for all indications held by reference rituximab (RTX)...
August 2, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28761603/-malignant-non-hodgkin-s-lymphoma-of-the-breast-and-hiv-about-a-case
#17
Ahmed Meklaa, Abdennasser El Kharass
Malignant non-Hodgkin's lymphoma (NHL) accounts for 0.5% of all breast cancers. Diagnosis is essentially based on histology. We report the case of a 42-year old female patient with MNHL of the breast and positive HIV serology. This study aimed to highlight the clinical, radiological and therapeutic aspects of this disease and to emphasize the importance of HIV testing in patients with extraganglionar MNHL.
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28761209/extranodal-non-hodgkin-s-lymphoma-of-the-oral-cavity-a-case-report
#18
Babyamma Raghavan Varun, Nettiyat Oommen Varghese, Trivandrum Thanappan Sivakumar, Anna Palliath Joseph
Lymphomas are solid malignant tumors having a wide spectrum of clinical and pathological features. Non-Hodgkin's lymphoma (NHL) is a subtype of lymphoma with two-thirds of the cases presenting as lymph node enlargement. The remaining one third of NHL cases has been reported in the extranodal sites, including the gastro intestinal tract, Waldeyer's ring, bone, skin, and brain. Intraoral non-Hodgkin's lymphoma is uncommon and may affect either the jaw bones or occur within the soft tissues of the oral cavity...
July 2017: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/28759103/contribution-of-solid-organ-transplant-recipients-to-the-pediatric-non-hodgkin-lymphoma-burden-in-the-united-states
#19
Elizabeth L Yanik, Meredith S Shiels, Jodi M Smith, Christina A Clarke, Charles F Lynch, Amy R Kahn, Lori Koch, Karen S Pawlish, Eric A Engels
BACKGROUND: Pediatric solid organ transplant recipients have a 100 to 200 times higher risk of non-Hodgkin lymphoma (NHL) than the general pediatric population. Consequently, transplant-related NHL may contribute considerably to the pediatric NHL burden in the United States. METHODS: A cohort study using a linkage between the US transplant registry and 16 cancer registries was conducted. Cancer incidence rates were calculated for people less than 20 years old in the transplant and general populations...
July 31, 2017: Cancer
https://www.readbyqxmd.com/read/28758262/paraneoplastic-pemphigus-seen-in-4-patients-with-hematologic-malignancies-formerly-treated-with-rituximab
#20
C Baykal, S Kılıç, R Küçükoğlu
Paraneoplastic pemphigus (PNP) is a peculiar variant of pemphigus with pathognomonic clinical, histological, and immunological features. It is typically associated with hematologic malignancies (84%), such as non-Hodgkin lymphomas (NHL) (most common), chronic lymphocytic leukemia (CLL), Castleman disease, thymoma, Waldenström's macroglobulinemia, Hodgkin lymphoma, and monoclonal gammopathy, as well as non-hematological neoplasms, such as epithelial carcinomas, mesenchymal sarcomas, and malignant melanoma. This article is protected by copyright...
July 31, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
17878
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"